MDACC Study No:2010-0811 ( NCT No: NCT01088048)
Title:A Phase I Study to Investigate the Safety and Clinical Activity of Idelalisib in Combination with Chemotherapeutic Agents, Immunomodulatory Agents, and Anti-CD20 mAb in Subjects with Relapsed or Refractory Indolent B-cell Non- Hodgkin Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia
Principal Investigator:Nathan Fowler
Treatment Agent:Bendamustine HCl; CAL-101; Ofatumumab; Rituximab
Study Status:Terminated
Study Description:The goal of this clinical research study is to learn about the safety of giving
Idelalisib (also known as CAL-101) in combination with rituximab, ofatumumab,
bendamustine, fludarabine, chlorambucil, everolimus, and bortezomib to patients
with NHL, MCL, or CLL. In another part of the study, participants will receive
Idelalisib with rituximab and lenalidomide. Researchers also want to learn if
this study drug combination can help to control the disease.
Hide details for General InformationGeneral Information

Disease Group:Lymphoma
Phase of Study:Phase I
Treatment Agents:Bendamustine HCl
Treatment Location:Both at MDACC & and Other Sites
Estimated Length of Stay in Houston:
Supported By:Gilead Sciences, Inc.
Return Visit:
Home Care:

Hide details for Study Contact InformationStudy Contact Information

Physician Name:Nathan Fowler
For Clinical Trial Enrollment:713-792-2860
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)

Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults